
Search Clinical Trials
Sponsor Condition of Interest |
---|
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy...
National Cancer Institute (NCI)
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
This phase II/III trial studies how well radiation therapy works when given together with
cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with
high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous
cell).... expand
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab. Type: Interventional Start Date: Mar 2013 |
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney...
Roswell Park Cancer Institute
Clear Cell Renal Cell Carcinoma
Stage IV Renal Cell Cancer
This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and
bevacizumab and to see how well they work in treating patients with previously untreated
kidney cancer that has spread to other places in the body (metastatic). Pazopanib
hydrochloride... expand
This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as bevacizumab, can prevent tumor growth by blocking the ability of tumor cells to grow and spread. Giving pazopanib hydrochloride together with bevacizumab may kill more tumor cells. Type: Interventional Start Date: Oct 2012 |
Web Based Orthopaedic Sports Medicine Registry
Arthrex, Inc.
Degenerative and Traumatic Pathology of the Knee
Degenerative and Traumatic Pathology of the Shoulder and Elbow
Degenerative and Traumatic Pathology of the Foot and Ankle
Degenerative and Traumatic Pathology of the Hand and Wrist
Degenerative and Traumatic Pathology of the Hip
The purpose of this study is to establish an international, web based clinical registry to
collect baseline characteristics of patients undergoing orthopaedic, sports medicine,
arthroscopy, and related surgery, and the subsequent outcomes and cost-effectiveness
associated... expand
The purpose of this study is to establish an international, web based clinical registry to collect baseline characteristics of patients undergoing orthopaedic, sports medicine, arthroscopy, and related surgery, and the subsequent outcomes and cost-effectiveness associated with the surgical procedures and nonoperative treatments. Type: Observational [Patient Registry] Start Date: Sep 2010 |
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a...
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC
HER2 Exon 20 Mutation
This is a randomized, positive-controlled, open-label, international multicenter, Phase 3
clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients
with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based... expand
This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based chemotherapy. Type: Interventional Start Date: Sep 2020 |
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation...
Siddhartha Ganguly
T Cell Lymphoma
For participants with CD30 positive Mature T-cell lymphomas who have received brentuximab
vedotin, cyclophosphamide, doxorubicin, and prednisone (A-CHP) as induction (4 to 6 cycles)
and achieved complete response (CR) or chemo-sensitive partial response (PR) and deemed
suitable... expand
For participants with CD30 positive Mature T-cell lymphomas who have received brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A-CHP) as induction (4 to 6 cycles) and achieved complete response (CR) or chemo-sensitive partial response (PR) and deemed suitable for autologous stem cell transplant (ASCT) as consolidation, the investigators propose to add brentuximab vedotin after ASCT. There is currently no standard of care treatment to prevent relapse after upfront treatment or ASCT for CD30-positive peripheral T-cell lymphoma's (PTCL)s. An agent that could improve outcomes in this population would be a major contribution to the field and is likely to be practice changing. Therefore, in addition to studying the anti-lymphoma activity of A-CHP as induction therapy, for participants who respond to induction the investigators propose to add brentuximab vedotin consolidation after ASCT in participants treated with consolidative upfront ASCT. Type: Interventional Start Date: May 2020 |
A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects...
Jazz Pharmaceuticals
Acute Myeloid Leukemia
Study CPX351-103 is an open-label, multicenter, phase 1b, safety and PK study to determine
the MTD of the combination of CPX 351 and venetoclax when administered to subjects with newly
diagnosed AML who are unfit for intensive chemotherapy (ICT). This study will comprise 2... expand
Study CPX351-103 is an open-label, multicenter, phase 1b, safety and PK study to determine the MTD of the combination of CPX 351 and venetoclax when administered to subjects with newly diagnosed AML who are unfit for intensive chemotherapy (ICT). This study will comprise 2 phases: a Dose Escalation Phase and an Expansion Phase, in which all subjects will receive a combination of CPX-351 and venetoclax. Type: Interventional Start Date: Oct 2019 |
Moderate-Intensity Exercise Versus High-Intensity Interval Training to Recover Walking Post-Stroke
University of Cincinnati
Stroke
The objective of this study is to determine the optimal training intensity and the minimum
training duration needed to maximize immediate improvements in walking capacity in chronic
stroke. A single-blind, phase II, 3-site randomized controlled trial has been planned. Fifty... expand
The objective of this study is to determine the optimal training intensity and the minimum training duration needed to maximize immediate improvements in walking capacity in chronic stroke. A single-blind, phase II, 3-site randomized controlled trial has been planned. Fifty persons >6 months post stroke will randomize to either moderate-intensity aerobic locomotor training or high-intensity interval locomotor training; each for 45 minutes, 3x/week for up to 36 total sessions over approximately 12 weeks. Clinical measures of walking function, aerobic fitness, daily walking activity and quality of life will be assessed at baseline (PRE) and after 4, 8 and 12 weeks of training (POST-4WK, POST-8WK, POST-12WK). Type: Interventional Start Date: Jan 2019 |
Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Virginia Commonwealth University
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
The TopCSPN trial is a double blinded randomized placebo controlled study of oral topiramate
as a potential disease modifying therapy for cryptogenic sensory peripheral neuropathy
(CSPN). Patients with CSPN who also have metabolic syndrome (defined by the ATPIII criteria)... expand
The TopCSPN trial is a double blinded randomized placebo controlled study of oral topiramate as a potential disease modifying therapy for cryptogenic sensory peripheral neuropathy (CSPN). Patients with CSPN who also have metabolic syndrome (defined by the ATPIII criteria) who do not have an alternative cause for neuropathy will be potentially eligible. The co primary outcome measures are change in the Norfolk Quality of Life - Diabetic Neuropathy (NQOL-DN) Scale and intraepidermal nerve fiber density (IEFND) at the distal thigh. The treatment phase will last 24 months. Type: Interventional Start Date: Feb 2018 |
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle...
ECOG-ACRIN Cancer Research Group
Liver Lymphoma
Mantle Cell Lymphoma
This phase II trial compares three chemotherapy regimens consisting of bendamustine,
rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating
patients with newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as
bendamustine... expand
This phase II trial compares three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating patients with newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This study is being done to find out if one the drug combinations of bendamustine, rituximab, high dose cytarabine, and acalabrutinib is better or worse than the usual approach for mantle cell lymphoma. Type: Interventional Start Date: Oct 2019 |
Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate...
ECOG-ACRIN Cancer Research Group
Prostate Carcinoma
This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works
in evaluating cancer stage and helping treatment planning in patients with prostate cancer.
Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive... expand
This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease. Type: Interventional Start Date: Jul 2018 |
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating...
ECOG-ACRIN Cancer Research Group
Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7
Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7
This randomized phase II trial studies how well chemotherapy before surgery and radiation
therapy works compared to surgery and radiation therapy alone in treating patients with nasal
and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such... expand
This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy before surgery and radiation therapy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed and treated with radiation. Type: Interventional Start Date: Mar 2018 |
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly...
Arog Pharmaceuticals, Inc.
Newly Diagnosed FLT3 Mutated AML
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with
that of midostaurin when administered following induction chemotherapy, consolidation
chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3
mutation.... expand
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treatment (arm B). Potentially eligible subjects will be registered and tested for the presence of FLT3 mutation. Once the FLT3 mutation status is confirmed and additional eligibility is established, subject will be randomized and enter into the treatment phase. Type: Interventional Start Date: Aug 2018 |
Zoster Eye Disease Study
NYU Langone Health
Herpes Zoster Ophthalmicus
This is a multi-center, randomized, double-masked, placebo-controlled clinical trial of
suppressive valacyclovir for one year in immunocompetent study participants with an episode
of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis
due... expand
This is a multi-center, randomized, double-masked, placebo-controlled clinical trial of suppressive valacyclovir for one year in immunocompetent study participants with an episode of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to Herpes Zoster Ophthalmicus (HZO) in the year prior to enrollment. Type: Interventional Start Date: Aug 2017 |
Activity for Diabetic Polyneuropathy
Virginia Commonwealth University
Diabetic Neuropathy
The proposed study will randomize participants with diabetic peripheral neuropathy into two
groups. One group of participants will receive standard-of-care counseling while the other
group will undergo supervised exercise and counseling to increase physical activity.
expand
The proposed study will randomize participants with diabetic peripheral neuropathy into two groups. One group of participants will receive standard-of-care counseling while the other group will undergo supervised exercise and counseling to increase physical activity. Type: Interventional Start Date: Nov 2015 |
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by...
ECOG-ACRIN Cancer Research Group
ALK Gene Rearrangement
ALK Gene Translocation
ALK Positive
Stage IB Non-Small Cell Lung Carcinoma AJCC v7
Stage II Non-Small Cell Lung Cancer AJCC v7
This randomized phase III trial studies how well crizotinib works in treating patients with
stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation
in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make... expand
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Type: Interventional Start Date: Aug 2014 |
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary...
ImmunoGen, Inc.
Epithelial Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer
This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine
(MIRV) in patients with platinum-resistant high-grade serous epithelial ovarian cancer,
primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate
Receptor-Alpha... expand
This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate Receptor-Alpha (FRα). Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. All patients will receive single-agent MIRV at 6 mg/kg adjusted ideal body weight administered on Day 1 of every 3-week cycle. Type: Interventional Start Date: Jul 2020 |
Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer...
Southwest Oncology Group
Rectal Carcinoma
Rectosigmoid Carcinoma
This phase II trial studies how a diet intervention works in improving bowel dysfunction
symptoms related in colon or rectal cancer survivors. Changing a diet may be helpful in
reducing the severity of bowel symptoms, including diarrhea and constipation, and improve
quality... expand
This phase II trial studies how a diet intervention works in improving bowel dysfunction symptoms related in colon or rectal cancer survivors. Changing a diet may be helpful in reducing the severity of bowel symptoms, including diarrhea and constipation, and improve quality of life in colon or rectal cancer survivors and help doctors learn how to help patients better in the future. Type: Interventional Start Date: Dec 2019 |
Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial
University of Kansas Medical Center
Pancreatic Cancer
The goal of this clinical research study is to learn if Niraparib can help to control
metastatic pancreatic cancer. The safety of this drug will also be studied. Niraparib is FDA
approved and commercially available for the treatment of ovarian cancer. Its use in this
study... expand
The goal of this clinical research study is to learn if Niraparib can help to control metastatic pancreatic cancer. The safety of this drug will also be studied. Niraparib is FDA approved and commercially available for the treatment of ovarian cancer. Its use in this study is investigational. Type: Interventional Start Date: Jan 2019 |
Omission of Radiation in Patients With Her-2 Positive Breast Cancer
University of Kansas Medical Center
HER2-positive Breast Cancer
The primary objective of this study is to describe the rate of local control in patients with
her-2 positive early stage breast cancer with a complete response to chemotherapy and
lumpectomy alone.
expand
The primary objective of this study is to describe the rate of local control in patients with her-2 positive early stage breast cancer with a complete response to chemotherapy and lumpectomy alone. Type: Interventional Start Date: Feb 2018 |
Central Nervous System Amplification in Lumbar Failed Back Surgery Syndrome
University of Kansas Medical Center
Chronic Pain
The purpose of this study is to learn whether or not certain risk factors and patient
characteristics are linked with and possibly can predict the development of chronic pain
after lumbar spine surgery.
expand
The purpose of this study is to learn whether or not certain risk factors and patient characteristics are linked with and possibly can predict the development of chronic pain after lumbar spine surgery. Type: Observational Start Date: Jun 2018 |
Comparison of VT Ablation Outcomes Using Remote MAGNETIC Navigation Versus Manual Approach in a Low LVEF...
Stereotaxis
Tachycardia, Ventricular
The study purpose is to demonstrate that ventricular tachycardia (VT) ablation using the
Niobe™ ES system results in superior outcomes compared to a manual approach in subjects with
ischemic scar VT in a low ejection fraction population.
expand
The study purpose is to demonstrate that ventricular tachycardia (VT) ablation using the Niobe™ ES system results in superior outcomes compared to a manual approach in subjects with ischemic scar VT in a low ejection fraction population. Type: Interventional Start Date: Jan 2016 |
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
Clear Cell Renal Cell Carcinoma
Metastatic Renal Cell Cancer
Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer
This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody
PF-04518600 work in treating patients with kidney cancer that has spread to other parts of
the body. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made... expand
This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made from living organisms that may may stimulate the immune system in different ways and stop tumor cells from growing. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving axitinib with or without anti-OX40 antibody PF-04518600 may work better in treating patients with kidney cancer. Type: Interventional Start Date: Jul 2017 |
Quality Improvement Center on Domestic Violence in Child Welfare
University of Kansas
Multiple Forms of Child Abuse
Domestic Violence
The Quality Improvement Center on Domestic Violence in Child Welfare (QIC-DVCW) is a
five-year federal cooperative agreement with the Children's Bureau to test an approach to
improve how child welfare agencies and their partners work collaboratively to help families
experiencing... expand
The Quality Improvement Center on Domestic Violence in Child Welfare (QIC-DVCW) is a five-year federal cooperative agreement with the Children's Bureau to test an approach to improve how child welfare agencies and their partners work collaboratively to help families experiencing domestic violence. The safety and well-being of child survivors of domestic violence and child maltreatment are closely connected to the safety and well-being of the adult survivor of domestic violence. For this reason, the QIC-DVCW is testing an Adult & Child Survivor-Centered Approach to addressing the needs of both the parent and child, which includes effectively engaging and working with the person causing them harm. The following four research questions were developed to guide the work of the Recipient's evaluation of the QIC-DVCW, and Provider's data will help to answer these questions: 1. Does a collaborative, adult and child survivor-centered approach-that includes safely engaging and establishing accountability of the DV offender-improve adult and child survivor safety, child permanence, and child and family well-being for child welfare involved families experiencing DV? 2. For which families and in which social contexts does an adult and child survivor-centered approach improve these outcomes? 3. What factors are associated with successful implementation and sustainability of an adult and child survivor-centered approach? 4. What are the costs associated with the implementation and maintenance of an adult and child survivor-centered approach, and how do these costs compare to the costs of "practice as usual"? Type: Interventional Start Date: Jan 2019 |
Analgesic Effect of Music Listening During Pain Elicitation in Fibromyalgia
University of Kansas Medical Center
Fibromyalgia
Patients with fibromyalgia (FM) are more sensitive to things that cause pain. Music lowers
self-reported pain in patients with chronic pain. The investigators are able to measure pain
sensitivity and pain tolerance using tools that cause pain and give accurate measurements of... expand
Patients with fibromyalgia (FM) are more sensitive to things that cause pain. Music lowers self-reported pain in patients with chronic pain. The investigators are able to measure pain sensitivity and pain tolerance using tools that cause pain and give accurate measurements of how much pressure is put on the body (QST). Previous studies have shown that after a few minutes of listening to music patients with FM have less self-reported pain, can get up and move from sitting more quickly, and have more activity in part of the brain that tells the body to stop sending pain signals. The investigators will study 40 patients with FM using the QST tools. All patients will have testing done as usual, with no sound. Then half of the patients will have testing done while listening to instrumental Classical music, and the other half will have testing done while listening to nature sounds. The investigators will test 1) whether listening to anything lessens pain compared to listening to nothing at all; and 2) whether listening to music lessens pain more than listening to nature sounds. Our study will be the first to study whether objectively measured pain sensitivity is less while listening to music in these patients. Type: Interventional Start Date: Dec 2019 |
HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
University of Kansas Medical Center
Prostate Cancer
Lower Urinary Tract Symptoms
To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower
urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for
patients concurrently diagnosed with prostate cancer.
expand
To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for patients concurrently diagnosed with prostate cancer. Type: Interventional Start Date: Sep 2019 |